Everyday Medicine with Dr Luke – Details, episodes & analysis

Memory is the cognitive process of acquiring, storing and retrieving information. It's the mind's ability to encode, store and recall experiences and knowledge, allowing for learning, adaptation, and the formation of personal identity. There are different types of memory, including short-term memory, where information is held briefly and long-term memory, where information is held for extended periods. There is sensory memory where information relating to senses such as sight, sound and smell are retained, explicit memory recalling memories or facts and events and implicit memory that influences our behaviour without conscious awareness; for example, like riding a bike or driving your car.

Memory storage involves multiple brain regions, but the hippocampus is crucial for forming new memories, especially long-term memories and acts as a gateway for encoding and consolidating memories. The cerebral cortex and prefrontal cortex also participate in memory storage and retrieval.

Without memory, our enjoyment of life’s wonderful pleasures and diversity is severely compromised. Unfortunately, memory loss is also a key feature of dementia and is often cited as an early clinical marker of cognitive decline in a patient who is starting to have difficulty coping with the complexity of life, their medication schedule, shopping lists and daily tasks.

I was curious to understand how we may improve and maintain our own memories whilst also providing advice in terms of exercises that may benefit our patients coping with early cognitive decline. The history of memory recall starts in Greece with Simonides of Ceos in ~500 BC. Simonides is credited with developing the ‘method of loci’ or ‘room method ‘of memory recall after an earthquake collapsed the roof at a banquet he had just attended, killing all inside. Relying on his visual memory, he was able to accurately identify the corpses by precisely recalling their seating arrangements as he had noticed them while he was reciting poetry to the guests. This method, now popularised by many teaching memory techniques, highlights the value of linking things we need to remember together to enhance their recall. It is also interesting that memory for music and songs is often retained until late in cognitive decline.

In an attempt to explore the ideas behind the complex subject of memory in more detail, it was an honour to have Dr Natalie Grima accept an invitation for the podcast. Natalie is a clinical neuropsychologist based in Melbourne and the founder of Neuro Psychological Counselling Australia. She is a senior clinical neuropsychologist at Monash Health and has published widely, completing her doctorate at Monash University and undertaking advanced clinical training at Harvard Medical School. Natalie has a special interest in the diagnosis of dementia, psychiatric conditions and cognitive rehabilitation following acquired brain injuries. She also has an expert knowledge on the subject of memory. Please welcome her to the podcast.

References:

Dr Natalie Grima: www.neuropychconsulting.com.au

https://mocacognition.com/

Simonides of Ceos-Wikipedia

Obesity has reached crisis levels in Australia, with 67% of Australians classified as being overweight or obese (2022 data). BMI measurements have been used in epidemiological studies to define overweight individuals with a measurement of 25 kilograms per metre squared and obese individuals with a BMI measurement of more than 30 kilograms per metre squared. It is now recognised, however, that BMI-based measures of obesity may both underestimate or overestimate adiposity and provide inadequate information about health at the individual level and subsequently undermine medically sound approaches to healthcare and policy. A recent Commission of 58 experts in this field reported a consensus in The Lancet defining obesity as "a condition characterised by excess adiposity, with or without abnormal distribution or function of adipose tissue and with causes that are multifactorial and still incompletely understood". They subsequently teased out the diagnosis of obesity to include preclinical and clinical definitions, where:

Pre-clinical obesity is defined by excess fat accumulation as measured by direct means with DEXA or indirect anthropometric measurements such as waist to height, waist circumference or waist to hip ratio measurement. This group of patients have no clinical disease or end-organ damage or symptoms as yet, but an increased risk of developing clinical obesity and conditions such as type 2 diabetes, cardiovascular disease and some neoplasms. The treatment focus in this group includes counselling and the introduction of measures to prevent progression to the next subgroup, which is clinical obesity.

Clinical Obesity is defined as a chronic, systemic illness characterised by alterations in the function of tissues, organs, the entire individual, or a combination thereof, due to excess adiposity. Clinical obesity can lead to severe end-organ damage, causing life-altering and potentially life-threatening complications. The main focus of management for this cohort is to improve end-organ dysfunction as a priority rather than to focus on weight loss alone. Treatment options include lifestyle modification through diet and counselling, and rely on established pharmacology such as GLP-1 receptor agonists, which are likely to be used as a long-term treatment strategy. For a select number of patients, however, these medications can induce nausea, vomiting, diarrhoea, constipation and reflux. In more serious cases gastro paresis and pancreatitis are described. Non-responsiveness and high cost may be a limiting factor amongst some patients. Consequently, surgery remains the cornerstone for safely and effectively managing obesity and includes both gastric sleeve and bypass operations.

To discuss this new definition of obesity and approach to thinking about obesity, as well as to review surgical options, I was curious to open a discussion with Dr Melissa Beitner. Melissa is a fellow of The Royal Australasian College of Surgeons; she is American Board of Surgery certified, a fellow of the American Society of Metabolic and Bariatric Surgery and is a diplomat of the American Board of Obesity Medicine. Melissa is incredibly well credentialed, having undertaken bariatric surgery fellowships at Mount Sinai Hospital in New York, Royal Brisbane and Women's Hospital and St. George Hospital, Sydney. She has special areas of interest in bariatric surgery and obesity medicine, and is also highly skilled in hiatus hernia and anti-reflux surgery, cholecystectomy and general surgical removal of lumps and bumps. Please welcome Meissa to the podcast.

References: 

Dr Beitner, Weight Loss Solutions: www.360surgery.com.au

Definition and Diagnostic Criteria of Clinical Obesity, F Rubino et al. The Lancet Diabetes and Endocrinology Commission. Vol 13, Issue 3, P221-262, March 2025

Artificial intelligence is a wide-ranging branch of computer science concerned with building smart machines capable of performing tasks that typically require human intelligence. It is widely accepted that artificial intelligence computer systems will be used extensively in Medical Sciences. Common applications are likely to include illness diagnosis, end-to-end drug discovery and development, improving communication between physicians and patients, transcribing medical documents, including history note taking and writing prescriptions. It is probable that as technology advances, doctors and allied health professionals will be replaced in certain roles by artificial intelligence computers. 

Artificial intelligence is not new and has been an important enabler within the technology industry, built into our handheld phone computer devices, enabling new business innovation, including web search content recommendations, product recommendations, targeted advertising and autonomously driven vehicles. Humans reap the benefits of artificial intelligence systems every day.

In medical practice, there are many advantages offered from embracing artificial intelligence, with the expectation that diagnostic accuracy and patient care will be the beneficiaries, whilst providing an excellent second opinion or co-collaborator with the physician, increasing medical efficiency and confidence in applying treatment strategies.

I was curious to learn more about the likely trends this technology might bring to health management and was fortunate to meet Anders Sorman- Nilsson at a recent medical conference where he provided our audience with a thought-provoking, entertaining and informative lecture on the future, including the possible integration of AI in medicine. As a global futurist and innovative strategist, Anders gave us a wonderful glimpse into a new world.

Anders has degrees in both law and political science as well as an EMBA, has keynoted at TED X in the United States and Australia and shared the stage with Hillary Clinton. He was nominated to the World Economic Forum's young global leaders in 2015 and has authored 3 books, including Seamless, Thinque Funky and Digilogue, as well as contributing to After Shock, edited by John Schroeter. Noting how meticulously researched and energetic his lecture was at our conference, I could strongly recommend Anders to anyone seeking an excellent keynote speaker who will provoke searching questions and prompt some deep thinking, possibly inspiring a new and creative approach to how you conduct business and prepare for the future. 

In this podcast, I was keen to explore the possible place of artificial intelligence in medicine, including how it could impact diagnostic assistance, drug discovery, provide virtual health assistance, enhance personalised medicine, as well as improve robot-assisted surgery. Other areas of interest extend to its place in influencing medical education and training, clinical trial optimisation, natural language processing for health records and how it may assist in both the sequencing of genomes and coping strategies for those requiring mental health support. It was a great privilege to speak to Anders today. Please welcome him to the podcast.

References: 

Anders Sorman-Nilsson found at: anderssorman-nilsson.com

Artificial Intelligence: How is it Changing Medical Science and Its Future? Basu et al.  https://www.ncbi.nlm.nih.gov

The Guillain Barre syndrome is an acute inflammatory demyelinating polyradiculopathy and although relatively rare (0.4-2 per 100,000) it is still the most common cause of acute flaccid neuromuscular paralysis worldwide. It famously affected Joseph Heller author of Catch-22 and more recently AFL football Legend Alexander Clarkson. It is an immune-mediated disorder that affects the peripheral nervous system and is another example of molecular mimicry, occurring 1 to 6 weeks after a respiratory infection, Campylobacter enterocolitis, and rarely after trauma or surgery. In 1 in a million cases, GB may develop after the influenza vaccine.

Myasthenia gravis is an autoimmune disorder most commonly observed in women under the age of 40 years and in men over the age of 60 years where antibodies form against the nicotinic acetylcholine receptor at the neuromuscular junction (85% of cases), muscle-specific tyrosine kinase (MuSK 7-10%) or low-density lipoprotein receptor-related protein 4 (LRP 4-5%)-the MuSK 7 and LRP4 are both important to the health of the neuromuscular junction. MG results in muscle fatigue especially of the eyes, facial muscles and bulbar muscles.

To discuss these two interesting conditions we are joined by associate Professor Ernie Butler who is the founder of Frankston neurology group and has major clinical expertise in the management of both acute and chronic neurological conditions, please join me in this conversation with Ernie.

To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au

Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.

Multiple sclerosis is an autoimmune neurodegenerative disease of the brain and spinal cord resulting in CNS demyelination affecting 2.8 million people worldwide and 23,000 Australians. There are about 1000 new cases diagnosed in Australia each year and the accumulation of disability can be devastating with an estimated 50 to 80% of patients ceasing full-time work within 10 years. The condition is 3 times more common in women and is most often seen between the ages of 20 and 40 years. The damage in multiple sclerosis is caused by a type IV hypersensitivity reaction and may reflect molecular mimicry with activated T cells crossing the blood-brain barrier and attacking CNS myelin which is produced by oligodendrocytes (myelin in the peripheral nervous system is made by Schwann cells).

Environmental and genetic factors play a role in the aetiology with a higher incidence of multiple sclerosis identified in patients living north of 40 degrees (north of Beijing and including much of Europe Russia the northern parts of the United States and Canada) or South of 40 degrees (Tasmania) raising speculation about the role of ultraviolet light and vitamin D. MS is 15 times more likely when a 1st-degree relative is affected and concordance with monozygotic twins is about 25%. Obesity, smoking, high intake of dietary saturated fats and Epstein-Barr virus have also been implicated.

Despite the distressing nature of this neurodegenerative condition many treatments are evolving to manage both acute episodes (steroids, plasmapheresis) and to prevent further damage (from Interferon beta and Glatiramer acetate to Ocrelizumab, Natalizumab and Stem cell therapy amongst others).
To guide us through this complex subject we are joined by associate Professor Ernie Butler who is the founder of Frankston neurology group and has a major clinical expertise in the management of multiple sclerosis amongst many other acute and chronic neurological conditions, please join me in this conversation with Ernie.

References:

Assoc professor Ernie Butler: Frankston neurology.com.au

www.ms.org.au

www.ninds.nih.gov , Multiple sclerosis : Hope Through Research

www.sciencedirect.com , Multiple Sclerosis-an overview

To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au

Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.

Neuroendocrine tumours represent neoplasms of the diffuse neuroendocrine system (DNES) which is our body’s largest endocrine organ comprised of the fascinating amine precursor uptake and decarboxylase (APUD) cell series first described in the 1960s by British scientist A.G.E Pearse. These cells can produce numerous peptides and bioactive amines. Influenced by both the endocrine and nervous systems as well as by the chemistry in their local environment, neuroendocrine cells play a vital role in intracellular signalling and ensure the integrated functioning of many organs and systems within the human body working in both paracrine and endocrine fashion. The signalling molecules produced by the diffuse neuroendocrine system represent a universal chemical language, a vital contributor to the regulation of homeostasis. Cells of the DNES are found throughout the body and are present in almost every organ with well-known examples in the lining of the Gi tract, the lungs, pancreas, thymus, thyroid, brain, adrenal glands etc…

Neoplastic transformation results in the development of neuroendocrine tumours (NET’S) most commonly in the small bowel (~60%) followed by the lungs (~27%) and pancreas.

Whilst considered rare more than 5000 diagnoses per year occur in Australia which is more than the combined number of annually reported pancreatic and gastric malignancies. Unfortunately, up to 60% of cases are advanced at the time of diagnosis with metastases and is not uncommon for patients to be misdiagnosed with irritable bowel syndrome. Neuroendocrine tumours may be functional or non-functional (the majority), they may be poorly or well-differentiated, low-grade or high-grade.

NET's have somatostatin receptors (there are 5 known receptors) on the cell surface and up to 80% of NET's express somatostatin receptor 2 which octreotide has a strong attraction for. The gallium dotatate scan exploits this fact by detecting the presence of the somatostatin 2 receptor.

Neuroendocrine cells also contain vesicles stacked with chromogranin which has been utilised as a relatively sensitive and specific marker for NET although elevated levels of this marker may be seen with proton pump inhibitors, renal impairment and atrophic gastritis. 24-hour measurement of urinary 5 hydroxy indole 3 acetic acids (5-HIAA), the degradation product of serotonin, is a useful laboratory marker for NETs producing serotonin.

I was particularly interested to explore this extensive subject further with Professor Rodney Hicks, Dr Michael Lee and Megan Rogers from the Peter MacCallum Cancer Centre all experts in managing neuroendocrine tumours and I was keen to discuss peptide receptor radionucleotide therapy (PRRT) which Professor Hicks whose expertise with this therapy is world renown. Please welcome them to this two-part podcast.

REFERENCES:

petermac.org

neuroendocrine.org.au

www.ncbi.nih.gov (Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours,2020)

www.sciencedirect.com

To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.

Neuroendocrine tumours represent neoplasms of the diffuse neuroendocrine system (DNES) which is our body’s largest endocrine organ comprised of the fascinating amine precursor uptake and decarboxylase (APUD) cell series first described in the 1960s by British scientist A.G.E Pearse. These cells can produce numerous peptides and bioactive amines. Influenced by both the endocrine and nervous systems as well as by the chemistry in their local environment, neuroendocrine cells play a vital role in intracellular signalling and ensure the integrated functioning of many organs and systems within the human body working in both paracrine and endocrine fashion. The signalling molecules produced by the diffuse neuroendocrine system represent a universal chemical language, a vital contributor to the regulation of homeostasis. Cells of the DNES are found throughout the body and are present in almost every organ with well-known examples in the lining of the Gi tract, the lungs, pancreas, thymus, thyroid, brain, adrenal glands etc…

Neoplastic transformation results in the development of neuroendocrine tumours (NET’S) most commonly in the small bowel (~60%) followed by the lungs (~27%) and pancreas.

Whilst considered rare more than 5000 diagnoses per year occur in Australia which is more than the combined number of annually reported pancreatic and gastric malignancies. Unfortunately, up to 60% of cases are advanced at the time of diagnosis with metastases and is not uncommon for patients to be misdiagnosed with irritable bowel syndrome.
Neuroendocrine tumours may be functional or non-functional (the majority), they may be poorly or well-differentiated, low-grade or high-grade.

NET's have somatostatin receptors (there are 5 known receptors) on the cell surface and up to 80% of NET's express somatostatin receptor 2 which octreotide has a strong attraction for. The gallium dotatate scan exploits this fact by detecting the presence of the somatostatin 2 receptor.

Neuroendocrine cells also contain vesicles stacked with chromogranin which has been utilised as a relatively sensitive and specific marker for NET although elevated levels of this marker may be seen with proton pump inhibitors, renal impairment and atrophic gastritis. 24-hour measurement of urinary 5 hydroxy indole 3 acetic acids (5-HIAA), the degradation product of serotonin, is a useful laboratory marker for NETs producing serotonin.

I was particularly interested to explore this extensive subject further with Professor Rodney Hicks, Dr Michael Lee and Megan Rogers from the Peter MacCallum Cancer Centre all experts in managing neuroendocrine tumours and I was keen to discuss peptide receptor radionucleotide therapy (PRRT) which Professor Hicks whose expertise with this therapy is world renown.
Please welcome them to this two-part podcast.

REFERENCES:

petermac.org

neuroendocrine.org.au

www.ncbi.nih.gov (Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours,2020)

www.sciencedirect.com

To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au

Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.

Pancreatic cancer is the eighth most common cancer reported in Australia. In 2021, it is estimated that there will be 4261 new cases and 3391 deaths. The incidence has increased from 10 per 100,000 in 1982 -to 12 per 100,000 today with the average age of onset between 60 and 65 years. At the time of diagnosis, approximately one-third of patients already have advanced disease with a limited 3 to 4-month survival prognosis, overall, 1-year survival for pancreatic cancer is only 16% and 5-year survival of 3% despite new approaches to management.

Risk factors include obesity, smoking (fivefold increase risk) and type 2 diabetes mellitus which after cigarette smoking and obesity is likely the third most modifiable risk factor for pancreatic cancer.

Other risks include family history (7%) and autosomal dominant syndromes such as Hereditary pancreatitis, Peutz-Jeghers syndrome, Hereditary breast and ovarian cancer syndrome (BRCA 2 and 1 genes), and Lynch syndrome and the Familial atypical multiple mole melanoma syndromes.

Additionally, there is probably a risk associated with ongoing heavy alcohol consumption and subsequent chronic pancreatic inflammation.

After imaging and subsequent diagnosis, staging determines locally respectable, borderline respectable, locally advanced unresectable or metastatic disease, and guides the choice of surgery, chemotherapy, radiotherapy and or palliation.

It was a privilege to be joined in this conversation by Dr Michael Lee from the Peter McCallum Cancer Centre, an oncologist specialising in clinical translational genomic research and advanced cancers with a special focus on metastatic pancreatic cancer. Michael trained in Australia and subsequently worked in Vancouver at the BC Cancer and Michael Smith's Science Centre before returning to Melbourne where he is undertaking a PhD with the aim of developing a new novel therapy for pancreatic cancer. Michael’s motto is to provide holistic oncology care with an honest conversation, supported by the latest research from the bench side to the bedside and tailoring it to his patient’s goals and wishes.

References:

www.petermac.org

canceraustralia.gov.au

www.cancer.org.au

www1.racgp.org.au

To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au

Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.

As case numbers and deaths continue to climb from Covid 19 infection and its many variants, two antiviral drugs have entered the market and are now available on the Australian PBS with specific prescription criteria to be met. So, what are they and what do they do?

Molnupiravir - Made by Merck in collaboration with Ridgeback Biotherapeutics was the 1st to be introduced to Australia as a trade named Lagevrio available from March 1st. This drug is a polymerase inhibitor administered as four tablets twice daily for a five-day course and works by stopping Covid 19’s genetic material from being replicated accurately. By inhibiting the virus’s own polymerase, it induces replication errors so that ultimately the virus is unable to survive with these. This is the so-called catastrophe method. A question for our guest relates to this drug’s safety…. for example: Could this drug also affect host enzymes?

Paxlovid - takes a different approach the drug consists of Nirmatrevir, and an existing drug called Ritonavir. These are protease inhibitors affecting the viral proteases which cut apart long strands of non-functional viral protein into smaller functional proteins. Nirmatrevir is the drug working on this whilst Ritonavir prevents other enzymes from destroying Nirmatrevir. Ritonavir may be found elsewhere and used in anti-HIV cocktails. Paxlovid is also taken BD for five days.

These drugs are most effective when given early and the PBS criteria states these drugs are for adults who have mild to moderate COVID-19 confirmed by a PCR or medically verified RAT and who can start treatment within 5 days of symptom onset if:

o they are 65 years of age or older, with two other risk factors for severe disease (as increasing age is a risk factor, patients who are 75 years of age or older only need to have one other risk factor); or

o they identify as Aboriginal or Torres Strait Islander origin and are 50 years of age or older with two other risk factors for severe disease, or

o they are moderate to severely immunocompromised.

We should draw attention to:

Evushield (Tixagevimab+ Cilgavimab) and Sotrovimab

We need a primer on who should receive these and will discuss this with our guest shortly.

And what about other drugs that have at times perhaps controversially been recommended around the globe such as?:

Chloroquine and Ivermectin

And then is there an early place for steroid prescription?

To expand our knowledge on this emerging and complex subject please welcome to the podcast Dr Alex Tai Infectious Diseases specialist with a special interest in public health, tropical medicine, multi drug microbial resistance and travel medicine.

For more information on this episode please visit: https://www.gihealth.com.au/everyday-medicine-podcast-blog/special-episode-11-anti-virals-for-covid-19-with-dr-alex-tai

References:

Dr Alex Tai-Infectious Diseases Physician-

www.bawbawphysicians.com.au

www.health.gov.au

What GPs need to know about the new Covid antivirals: www1.racgp.org.au

Antiviral treatments for Covid 19-NPS MedicineWise-www.nps.org.au

Liverpool COVID -19 Interactions : www.covid19-druginteractions.org

To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au

Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.

Lymphoma is a clonal neoplastic proliferation of lymphoid cells (B cells, T cells and NK cells) and is the sixth most common malignancy reported in this country which makes it the most common hematologic malignancy with over 5000 cases diagnosed each year in Australia putting lifetime risk at 1 in 50.

There are over 70 different types of lymphoma which are divided into 2 main groups: Hodgkin's lymphoma accounts for 10% of cases and non-Hodgkin's lymphoma accounts for 90% of cases.

Hodgkin's lymphoma named after Thomas Hodgkin (1832) is more common in men, and tends to occur at a younger age than non-Hodgkin's lymphoma with a bimodal age distribution but the average age at diagnosis of 39 years and involves lymph nodes frequently on just one side of the body usually above the diaphragm. The tumour cell is referred to as the Reed Sternberg cell which is a bi or multi-nucleated B cell comprising characteristically just 1% of the lymphoma mass. Just to make this nomenclature interesting there is classic Hodgkins which make up about 95 % of cases and of which nodular sclerosing comprises about 70 % and mixed cellularity 20-25 % and non-classic Hodgkins is characterised by nodular lymphocytic predominant pathology.
Non-Hodgkin's lymphoma can occur at any age and although the median age at diagnosis is 67 years it is one of the more common cancers among children, teens and young adults, none the less the risk of developing NHL increases throughout life and more than half the patients with NHL are 65 years or older at diagnosis. It is also more common amongst men and those with autoimmune diseases or a family history of hematologic malignancies. Presentations often involve the finding of involved lymph nodes on either side of the diaphragm. 85% of non-Hodgkin lymphomas are B cells in origin, and 15% are T cells. The most common the B cell non-Hodgkin lymphomas are diffuse large B cells -accounting for 37% of NHL cases, followed by follicular 29%, Malt 9% and Mantle cells 7%.
This is a complex and vast subject with a number of environmental factors and associated diseases influencing the fascinating pathogenesis of lymphoma which goes to the heart of B cell biology and our immune systems’ task of fighting for our lives against antigen invaders. There are a host of treatment options available with new emerging therapies at the cutting edge of medicine and it was a privilege to have a conversation with Professor Stephen OPAT -and to journey for a short time into his world of haematology. Stephen is the professor and director of clinical haematology at MMC and has a special interest in lymphoma, chronic leukaemia, cancer genomics and disorders of metabolism. I found Stevens’ conversation incredibly insightful and welcome you to this podcast:

References:

www.melbournehaematology.com.au

www.ncbi.nlm.nih.gov

www.cancer.org

www.uptodate.com

To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au

Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.